Zacks Investment Research upgraded shares of OncoCyte Corp (NYSE:OCX) from a sell rating to a hold rating in a research note issued to investors on Wednesday.
According to Zacks, “OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California. “
Separately, Chardan Capital reissued a buy rating and issued a $7.75 price target (up from $6.50) on shares of OncoCyte Corp in a report on Tuesday, May 23rd.
OncoCyte Corp (NYSE OCX) traded down 5.978% during mid-day trading on Wednesday, hitting $4.325. 32,928 shares of the stock were exchanged. OncoCyte Corp has a 52 week low of $3.35 and a 52 week high of $7.95. The stock’s 50-day moving average is $5.15 and its 200 day moving average is $5.66. The company’s market capitalization is $127.02 million.
COPYRIGHT VIOLATION NOTICE: This piece was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://stocknewstimes.com/2017/07/20/oncocyte-corp-ocx-stock-rating-upgraded-by-zacks-investment-research.html.
OncoCyte Corp Company Profile
OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment.
Get a free copy of the Zacks research report on OncoCyte Corp (OCX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OncoCyte Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte Corp and related companies with MarketBeat.com's FREE daily email newsletter.
